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The incidence of ST elevation myocardial infarction (STEMI) is around 66 STEMI per 100 000
of population/year, with 6–12% hospital mortality in unselected patients [1]. Modern
treatment strategies for STEMI are based on immediate antithrombotic treatment and
primary percutaneous coronary intervention (PCI) with stent implantation. Therapy with a
combination of two or even three more potent antiplatelet and anticoagulant agents
reduces both short-term and long-term ischemic risk, morbidity and mortality; on the
other hand it is associated with higher risks of bleeding. The first part of this review is
focused on the pathogenesis of thrombi in STEMI patients and antithrombotic drugs
currently used to treat STEMI patients. In the second part we discuss several factors that
can affect bleeding risks including the choice of access site for coronary angiography,
prevention and treatment of bleeding in STEMI patients. Finding a balance which
minimizes both thrombotic and bleeding risk is crucial, although, it can be difficult and
further randomized studies directed at finding this balance are needed.
& 2013 Published by Elsevier Urban & Partner Sp.z o.o. on behalf of The Czech Society of
Cardiology.
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Successful treatment of STEMI requires early diagnosis and
urgent neutralization of lesion through antithrombotic ther-
apy and mechanical revascularization. Modern antithrombo-
tic treatment in conjunction with primary percutaneous
coronary intervention (pPCI) has reduced morbidity and
mortality in STEMI patients [2]. Nevertheless, effective treat-
ment strategies may be associated with bleeding complica-
tions (Fig. 1). Depending on the study, the registry and the
data source used, 3–14% of STEMI patients experience bleed-
ing during the year following pPCI.
Bleeding in STEMI patients significantly prolongs intensive
care unit stay and increases mortality [3]. According to the
Thrombolysis In Myocardial Infarction (TIMI) bleeding cri-
teria, TIMI major bleeding increases mortality 5 times and
TIMI minor bleeding with transfusion increases the risks 2–3
times [4].
The efficacy, but also safety of antithrombotic drugs is
crucial because today we use more potent antiplatelet agents
and invasive strategies are now used to treat older patients
with comorbidities as well as patients with higher risks of
bleeding.
Current drug therapy in STEMI patients is based on evidence
both from clinical trials in ACS with ST segment elevation and
ACS without ST segment elevation or stable coronary artery
disease (CAD), because many etiological and pathophysiological
factors are similar. Therefore, in the part focused on antithrom-
botic drugs we discuss the results of trials across a broad
spectrum of CAD (not only STEMI). In addition, we comment
on experiences and trials from neurology and gastroenterologyFig. 1 – Delicate balance between ischemic and bleeding
risk.because these specialties have experience with the management
of intracranial or gastrointestinal bleeding complications in
patients on antithrombotic therapy. In summary, this review
article focuses on current antithrombotic drugs, bleeding risks
and complications in STEMI patients.2. Pathogenesis of thrombi in STEMI
STEMI represents the most lethal form of acute coronary
syndrome (ACS), in which a completely occlusive thrombus
results in total cessation of coronary blood flow in the region
of the infarct related artery and is associated with ST segment
elevation on an electrocardiogram (ECG). The majority of
myocardial infarctions (MIs) occur in patients with athero-
sclerotic stenosis associated with superimposed luminal
thrombi. Arbustini et al. found coronary thrombi in 98% of
patients dying from a clinically documented acute MI, and of
those thrombi, 75% were caused by plaque rupture and 25%
by plaque erosion [5].
Plaque rupture or erosion facilitates the interaction
between inner plaque components and circulating blood.
Tissue factor (TF) is a potent platelet activator and coagula-
tion trigger. Recent research has provided a very detailed
picture of the biochemical components and pathways
involved in platelet activation.
At the site of a vascular lesion, circulating von Willebrand
factor (vWF) binds to exposed collagen within the lesion,
which subsequently binds to the glycoprotein IB/IX receptor
on the membranes of platelets that are in the immediate
vicinity, vWF is secreted from storage organelles in platelets
and/or endothelial cells. Interaction of GP (glycoprotein)
IB/IX–vWF is enough to promote binding of platelets to the
subendothelium resulting in rapid accumulation of platelets
in the site of lesion. GP VI binding to matrix collagen has
slower binding kinetics, but when initiated, it promotes firm
adhesion of platelet to the vessel surface.
Exposed matrix within a vessel wall and thrombin gener-
ated by activation of the coagulation cascade, as well as
epinephrine and adenosine diphosphate are powerful platelet
agonists. Each agonist stimulates the discharge of calcium
and promotes the subsequence release of the platelet’s
granular content.
Adenosine diphosphate (ADP) released from platelet dense-
granules as well as injured cells binds to the P2Y12 receptors and
then induces activation of the GP IIb/IIIa receptor and platelet
aggregation. P2Y12 plays a central role in amplification and
stabilization of ADP-induced platelet aggregation.
Cyclooxygenase 1 (COX-1) is the key enzyme in prosta-
glandin biosynthesis. It converts free arachidonic acid,
released from platelet membranes, to thromboxane A (TXA).
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vasoconstrictor. The initial recognition of a damaged vessel wall
by platelets involves adhesion, activation and aggregation.
After the initial layer of platelets has spread over the
lesion, additional platelets aggregate to form a secondary
and tertiary layer of platelets (connection IIb/IIIa receptor–
fibrin–IIb/IIIa receptor) and eventually form a white thrombus.
In the final step there is recruitment of other cells, e.g.
erythrocytes, neutrophils, monocytes, etc. [6].3. Antithrombotic drugs
3.1. Classification of used antiplatelet agents (Fig. 2)1. Aspirin blocks cyclooxygenase 1 (COX-1).2. Platelet P2Y12 blockers inhibit ADP receptors
 ticlopidine, clopidogrel, prasugrel (irreversible inhibitors)
 cangrelor and ticagrelor (reversible inhibitors)3. Glycoprotein IIb/IIIa inhibitors block bridging of platelets
by fibrinogen—abciximab, eptifibatide, tirofiban.4. Thrombin receptor antagonist PAR (protease-activated
receptor)—vorapaxar, atopaxar (currently tested in clinical
trials).
The ESC guidelines for STEMI 2012 recommend aspir-
inþone of the newer P2Y12 blockers (prasugrel or ticagrelor)
preferred over clopidogrel [7].
3.1.1. Aspirin (acetylsalicylic acid)
Complete inhibition of platelet aggregation using aspirin
usually requires a dosage of about 75 mg/day. It results in
an inactive COX-1 enzyme for the remaining lifespan of the
platelet (7–10 days). The restoration of normal platelet func-
tion, after aspirin administration, occurs only with the
production of new platelets. One seventh of circulating
platelets are renewed every 24 h; therefore, up to 30% of
circulating platelets may show normal TxA2 production after
aspirin discontinuation for 48 h. Low dose aspirin does not
affect the action of endothelial cell COX-1 and therefore does
not reduce the production of PGI2, which has many beneficial
effects including potent antiplatelet effects.
A meta-analysis of 6 randomized trials (2427 patients with
a history of myocardial infarction and 1757 patients with a
history of transitory ischemic attack or stroke) showed that
aspirin substantially reduces all-cause mortality by approxi-
mately 18% and nonfatal vascular events by 30% [8].
The optimal dose for efficacy and safety remains debatable.
The results of CURRENT-OASIS 7 trial showed that in patients
with ACS (25,086 patients studied, 29% STEMI and 71% non-
STEMI or unstable angina pectoris), there was no significant
difference after 30 days with regard to the primary outcome
(cardiovascular death, MI, stroke) or major bleeding between
the higher (300 mg daily) and lower (100 mg daily) dose
aspirin groups. This finding was similar in the higher dose
and lower dose clopidogrel groups [9].
An analysis of an Italian trial (189,425 individuals from the
general population taking low dose aspirin) by Berardis and
colleagues showed the overall rate of major bleeding eventsper 1000 persons/year was 5.58 for aspirin users compared
with 3.60 for non-aspirin users (incidence rate ratio 1.55
(95% CI, 1.48–1.63)) [10].
Continuing usage of low-dose aspirin after endoscopic
treatment of a bleeding peptic ulcer (in patients with cardi-
ovascular disease on aspirin) raises the risk of additional
bleeding but may also reduce mortality rates, according to a
report from Sung et al. Seventy five patients with peptic ulcer
bleeding were assigned to receive aspirin (80 mg/day) and 75
patients receive a placebo for 8 weeks after endoscopic
therapy. All subjects received intravenous pantoprazole
(80 mg bolus, 8 mg/h for 72 h, followed by oral pantoprazole
(40 mg/day) until the end of the study). The rate of recurrent
ulcer bleeding at 30 days was nearly twice as high in the
aspirin group compared to the placebo group: 10.3% vs. 5.4%
(p¼0.25). However, the all-cause mortality rate at 8 weeks
was much lower in the aspirin group: 1.3% vs. 12.9% (po0.01)
due to the reduction of cardiovascular and cerebrovascular
complications [11].
3.1.2. P2Y12 receptor antagonists
The important role of the P2Y12 receptor in platelet activation
and thrombus formation has made it a crucial target in the
management and prevention of arterial thrombosis.
Clopidogrel is an intestinally absorbed prodrug that is
converted to its active metabolite in the liver by cytochrome
P-450. It is estimated that approximately one-third of
clopidogrel-treated patients exhibit a diminished platelet
response to clopidogrel. The results of the CURRENT OASIS
7 trial in ACS patients showed a non-significant benefit of
150 mg/day over 75 mg/day clopidogrel in the whole popula-
tion. However, a subgroup analysis showed a benefit
from increased clopidogrel dose during the first week in
ACS patients treated with PCI [12].
Is clopidogrel safer than aspirin with the respect of
bleeding rate? The results of CAPRIE study (19,185 patients
with atherosclerotic vascular disease that manifested as
either a recent MI, ischemic stroke or symptomatic peripheral
arterial disease) did not show significant differences in major
bleeding between aspirin (300 mg/day) and clopidogrel
(75 mg/day) group [13].
The MATCH trial (8600 patients with recent ischemic
stroke or transient ischemic attack and at least one vascular
risk factor) documented that the use of clopidogrel
75 mgþaspirin 75 mg caused more life-threatening bleeding
than clopidogrel alone. At 18 months dual anti-platelet (DAPT)
therapy increased life-threatening bleedings (2.6% vs. 1.3%);
absolute risk increase 1.3 (95% CI 0.6–1.9). Major bleeding was
also increased in the group receiving aspirin and clopidogrel
but no difference was recorded in mortality [14].
The utility of tailored treatment with clopidogrel based on
platelet function tests is now widely discussed.
The GRAVITAS study (2800 patients with ACS without ST
segment elevation undergoing PCI and drug eluting stent
implantation) showed that although doubling the clopidogrel
maintenance dose in poor responders may improve the
measured response, it does not necessarily improve out-
comes [15]. In addition, the large clinical ARCTIC trial (2440
patients without STEMI, who were scheduled to undergo PCI
with drug-eluting stents) did not confirm any significant
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monitoring and treatment adjustment for coronary stenting,
compared with standard antiplatelet therapy without mon-
itoring [16].
Genetic testing before starting clopidogrel therapy, in
high-risk patients, and platelet function testing, in those
who suffer adverse events, may facilitate the monitoring of
clopidogrel treatment.
The possible interaction between clopidogrel and proton
pump inhibitors is mentioned below (section on prevention
of bleeding).
The next two drugs, prasugrel and ticagrelor are faster in
action, more potent and more predictable than clopidogrel
[17] and thus should be the preferred in combination with
aspirin if not contraindicated.
Prasugrel is a pro-drug, its active metabolite appears in
the circulation within 15 min of receiving a 60 mg loading
dose [18]. In patients with documented CVD undergoing
cardiac catheterization with PCI for angina pectoris, a 60 mg
loading dose of prasugrel resulted in greater platelet inhibi-
tion than a 600 mg loading dose of clopidogrel [19]. Further-
more, a prasugrel maintenance dose of 10 mg/day results in
more potent and consistent inhibition of platelet activation
than a clopidogrel maintenance dose of 75 or 150 mg/day.
In the TRITON-TIMI 38 study, reduced rates of ischemic
events (especially in diabetic or STEMI patients), including
stent thrombosis in ACS patient undergoing PCI, were seen in
prasugrel treated patients compared to the clopidogrel group.
On the other hand, an increased rate of serious bleeding and
fatal bleeding was also observed. Overall mortality did not
differ between the two treatment groups [20].
In a subgroup of STEMI patient’s prasugrel and clopidogrel
had similar safety profiles with respect to bleeding. Following
15 months of treatment, the rate of TIMI major and minor
non-CABG bleeding in prasugrel and clopidogrel treated
patients were comparable (5.1% vs. 4.7%, p¼0.65). Further-
more, prasugrel, compared with clopidogrel, did not signifi-
cantly increase the rate of life-threatening bleeding (1.3 vs.
1.1%, respectively) [21].
The recommendation for discontinuing of prasugrel prior
to cardiac surgery is 7 days. Prasugrel should not be adminis-
tered to patients with a prior history of strokes or transient
ischemic attacks. In patients aged 475 years, prasugrel is
generally not recommended because of the increased risk of
fatal and intracranial bleeding and the uncertain benefit;
additionally, consideration should be given to lowering the
maintenance dose to 5 mg in patients weighing o60 kg.
In the TRILOGY trial, prasugrel failed to show a reduction
in major cardiovascular events compared with clopidogrel in
patients with acute coronary syndrome (ACS) with non-ST
segment elevation and who were managed medically, i.e.
without revascularization [22]. Interestingly, there were no
differences (at the 30 months follow up) between the prasu-
grel and clopidogrel group in patients o75 years and the
overall population relative to rates of global use of strategies
to open occluded coronary arteries (GUSTO); severe/life-
threatening and TIMI major bleeding; and fatal and intracra-
nial bleeding. A lower dose of prasugrel (5 mg) was used in
those aged Z75 years and in those weighing less than 60 kg
and appeared to be safe.Ticagrelor is a nucleoside analog absorbed quickly from
the gut and reaches peak concentration after 90 min. The
drug plus its main metabolite are both pharmacologically
active and are mainly excreted via bile and feces.
In the PLATO study (ticagrelor vs. clopidogrel), in patients
with ACS, 7544 patients had STEMI. In these patients, a 13%
reduction in the primary end point (incidence of MI, stroke or
vascular death) was observed. There was no significant
difference between the two trial arms with respect to any
category of bleeding (major, minor, life-threatening, CABG or
non-CABG related), except for the combination of no-
procedure-related major and minor bleeding, which was
more common with ticagrelor than with clopidogrel (5.1%
vs. 3.7%) [23].
Contraindications for ticagrelor are a history of intracra-
nial bleeding, as well as reduced liver function. Ticagrelor
should be indicated with caution in patients with bradycardia
or severe chronic obstructive pulmonary disease (COPD).
Cangrelor is parenteral P2Y12 inhibitor with very short
half-life; restoration of platelet function is observed within
60 min of drug discontinuation. This pharmacokinetic char-
acteristic might be advantageous relative to urgent surgery.
However, in the Champion PCI study, cangrelor failed to show
a benefit over clopidogrel [24,25].3.1.3. Glycoprotein IIb/IIIa inhibitors
Abciximab, the most widely used agent from the glycoprotein
(GP) IIb/IIIa inhibitors is indicated as an addition to dual
antiplatelet drug therapy (DAPT) in pPCI for the prevention
of cardiac ischemic complications in patient with angio-
graphic evidence of a large thrombus, TIMI flow 0–1, or other
thrombotic complications, e.g. distal embolism [26].
The onset of abciximab effect (bolus rate) is less than
10 min. Its modification of platelet function last for up to 48 h
after the infusion has been terminated, and low levels of GP
IIb/IIIa receptor blockade are present for up to 15 days after
the infusion is terminated.
In the STEMI–abciximab meta-analysis [27], major bleed-
ing complications were higher with abciximab than placebo
(4.7% vs. 4.1%; OR 1.16, p¼0.36), intracranial bleeding was
the same.
Gu et al. studied 534 patients with STEMI and compared
intracoronary (i.c.) abciximab to intravenous (i.v.) adminis-
tration [28]. They found no difference relative to the com-
bined endpoint of death, reinfarction or congestive heart
failure. However, myocardial reperfusion, as assessed using
myocardial blush and infarct size, were improved in the
intracoronary group. Infarct size was similarly reduced, by
about 30%, when measured using either creatine kinase-MB
or cardiac troponin T. But cardiac enzyme was obtained in
only 46% of patients. The incidence of in hospital major and
minor bleeding was low and similar in both groups.
In meta-analysis from 8 randomized trials with 3259
patients by De Luca et al. [29] was documented that i.c.
administration of abciximab is associated with significant
benefits in myocardial perfusion but not in clinical outcome
at the short-term follow-up compared to i.v. abciximab
administration, without any excess in major bleeding in
STEMI patients undergoing pPCI.
Fig. 2 – Mechanism of platelet adhesion, activation and aggregation [6]. ATP—adenosin triphosphate, ADP—adenosin
diphosphate, GP—glycoprotein, 5-HT—hydroxytriptamine, PAR—protease activated receptor, Rc—receptor, TXA—thromboxane,
vWF—von Willebrand factor, TP-Rc - Thromboxane receptor.
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i.c. vs. i.v. abciximab and found a similar rate for the primary
composite clinical endpoint-death/MI/heart failure at 90 days
(7.0% vs. 7.6%; OR [95% CI] 0.91 [0.64–1.28], p¼0.58).
For death, the results showed non-significant difference
(4.5% vs. 3.6%; OR 1.24 [0.78–1.97] p¼0.36). Reinfarction also
did not differ between the treatment groups (1.8% vs. 1.8%;
OR 1.0 [0.51–1.96] p¼0.99), whereas less patients in the
intracoronary group had new congestive heart failure (2.4%
vs. 4.1%; OR 0.5 7 [0.33–0.97] p¼0.04). Bleeding was not
significantly different between i.v. vs. i.c. groups.
To date, there is no experience using combinations of
abciximab and any of the newer anti-platelet agents, such as
prasugrel or ticagrelor; however, such a coadministration
could increase the risk of bleeding and therefore should be
used with caution.
Eptifibatide is a peptide that reversibly binds to GP IIb/IIIa
receptors. It has a very short half-life; as an example, four hours
after cessation of infusion, patients have safely undergone CABG.
The large SCAAR registry (11,000 STEMI patients) suggests
that eptifibatide is not inferior to abciximab in STEMI patients
undergoing primary PCI with respect to the occurrence of
death or MI at the 1 year follow up; this supports the use of
either drug in clinical practice [31].
In patients after recent primary PCI with stent implanta-
tion, who require cessation of P2Y12 before surgery, bridgingwith GP IIb/IIIa inhibitors appears effective in preventing
adverse cardiac events; however, it may be associated with
bleeding in patients undergoing cardiac surgery [32].
At the 3-year follow-up of the HORIZONS-AMI trial, epti-
fibatide and abciximab had comparable bleeding risks and
clinical efficacy in patients after primary PCI [33].3.2. Anticoagulants
In STEMI patients, 3 agents are recommended [7]:1. Bivalirudin (level of evidence-LOE: IB)2. Enoxaparin (LOE IIbB)3. Unfractionated heparin (should be used in patients not
receiving bivalirudin or enoxaparin, LOE IC)The most frequent used anticoagulant in practice today is
unfractioned heparin (UFH). It is a drug with long history, much
experience and has an effective antidote (protamine). Bivalir-
udin is a specific and reversible direct thrombin inhibitor. In the
HORIZONS-AMI study, the superiority of bivalirudin was
demonstrated over a combination of UFHþabciximab. This
study reported reduction in all cause and cardiovascular (CV)
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also reduced [34].
In a retrospective study of 900 US patients, bivalirudin was
compared to heparin (without GP IIb/IIIa inhibitors). The
results confirmed a similar safety and efficacy profile for
both drugs [35].
Enoxaparin is recommended as an alternative to UFH or
bivalirudin. Comparison of enoxaparin vs. UFH in the ATOLL
study showed that enoxaparin reduced the combined
ischemic endpoint of death, reinfarction or urgent revascular-
ization (8.5% vs. 5.1%, p¼0.04). The incidence of major bleed-
ing did not differ between groups ([5%] vs. [5%]; p¼0.79) [36].0
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Bleeding events are important end points for the assessment of
drugs and safety profiles during randomized trials. There are
many data from several trials relative to bleeding, but unfortu-
nately, to date, there has been a lot of non-homogeneity
regarding the definition of bleeding and its categorization (i.e.
minor, moderate, major, life-threatening, severe, serious, with
need of transfusion, etc.) and many different classification are
used, e.g. TIMI [37] (Table 1) GUSTO [38], STEEPLE, GRACE,
PLATO etc. Therefore, it is difficult to compare results between
trials (Fig. 3) [39]. In 2010, academic research on bleeding and
drug administration developed new a universal bleeding classi-
fication for cardiovascular clinical trials, called the BARC classi-
fication [40], which consists of 5 types of bleeding (Table 2).
Rates of bleeding complications have been steadily drop-
ping after elective percutaneous coronary interventions
according to registry data published in May 2012 [41]. How-
ever, the decrease was not seen in STEMI patients.
Based on the results from many studies, several important
predictors of bleeding are known (Fig. 4). The most common
is age; other strong predictors are shock, use of anticoagulant
treatment and/or NSAIDs, prior history of bleeding, renal
failure, comorbidities (sepsis and mechanical ventilation and
diabetes mellitus). Other predictive factors include: low body
weight, obesity, anemia and female gender. Moreover, anti-
thrombotic treatment strategies (e.g. the use of GP IIb/IIIa
inhibitors) also play an important role [42].
The relationship between bleeding and mortality is both
direct and indirect. Intracranial and gastrointestinal hemor-
rhages are well recognized as potentially fatal events. However,
consequences of bleeding may have other detrimental effects:Fig. 3 – Bleeding incidence. Impact of bleeding definition
[40]. N¼15,858 acute coronary syndrome patients from(1)T
M
M
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Interactions between activated platelets and clotting cas-
cade produce a rapid hemostatic response at site ofable 1 – TIMI bleeding classification [37].
ajor  Any intracranial hemorrhage
 Clinically overt signs of hemorrhage associated with a drop in
 Fatal bleeding (bleeding that directly results in death within
inor  Clinically overt (including imaging), resulting in hemoglobin
 No observed blood loss: Z4 g/dL decrease in the hemoglobin
inimal  Any clinically overt sign of hemorrhage (including imaging) a
o9% decrease in hematocrit
MI—Thrombolysis In Myocardial Infarction.vascular injury and deficiency of an antithrombotic pro-
tective mechanism;(2) Further, procoagulation factor i.e., increased erythropoie-
tin synthesis in response to anemia caused by bleeding.
Systemic prothrombotic states might last beyond the
acute phase, by causing platelet activation and inducing
plasminogen activator inhibitor-1 synthesis; [43](3) In the presence of severe bleeding antithrombotic medi-
cation is almost always withdrawn or reduced at least
temporarily;(4) Finally, the use of transfusions has prothrombotic effects
and increases mortality in STEMI patients [44].
A meta-analysis of the REPLACE-2, ACUITY and
HORIZONS-AMI trials performed by Mehran et al. showed
that non-CABG related bleeding within 30 days was strongly
associated with an increased risk of 1 year mortality in
patients undergoing PCI for all indications [4].5. Source of bleeding after STEMI
Post-STEMI bleeding is divided into access site (40–50%) and
non-access site bleeding (50–60%). As mentioned earlier, the
ratio between access site and non-access site bleeding found
in different studies varies depending on the bleeding classi-
fication used. Several factors appear to influence the reported
rate of bleeding complications in clinical trials, including: (1)hemoglobin ofZ5 g/dL or aZ15% absolute decrease in hematocrit
7 days)
drop of 3 to o5 g/dL or Z10% decrease in hematocrit
concentration or Z12% decrease in hematocrit
ssociated with a o3 g/dL decrease in hemoglobin concentration or
Table 2 – Bleeding Academic Research Consortium (BARC) definition for bleeding [40].
Type 0 No bleeding
Type 1  Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies,
hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation
of medical therapy by the patient without consulting a healthcare professional
Type 2  Any overt, actionable sign of hemorrhage (e.g., more bleeding than would be expected for a clinical
circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3
Type 3 Type 3a
 Overt bleeding plus hemoglobin drop of 3–5 g/dL
Type 3b
 Overt bleeding plus hemoglobin drop 45 g/dL
 Cardiac tamponade
 Bleeding requiring surgical intervention for control
 Bleeding requiring intravenous vasoactive agents
Type 3c
 Intracranial hemorrhage
Type 4 CABG-related bleeding
 Perioperative intracranial bleeding within 48 h
 Reoperation after closure of sternotomy for the purpose of controlling bleeding
 Transfusion of 45 U whole blood or packed red blood cells within a 48-h period
 Chest tube output 42 L within a 24-h period
Type 5 Fatal bleeding
Non-modifiable Modifiable
Fig. 4 – Predictors of bleeding. PPI—proton pump inhibitor.
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invasive procedures, (3) bleeding definition, and (4) anti-
thrombotic agents used [45].5.1. Non-access site bleeding
The gastrointestinal (GI) tract is the most common non-
access site bleeding (1 year incidence 0.7–3.5%). The greatest
risk is previous GI bleeding. The majority of bleeding is in
upper GI tract (ulcer or erosion of stomach, duodenum and
esophagus). Prevention and treatment are discussed below.
Intracranial bleeding (0.1–0.4%) is the most serious loca-
tion of bleeding. In the thrombolytic era, the incidence of
intracranial bleeding between streptokinase vs. alteplase
treated patients was 0.5% vs. 0.7%, p¼0.03 (GUSTO trial) [38].In the era of primary PCI, the incidence of intracranial
bleeding has dropped below 0.4% per 1 year for STEMI.
In intracranial bleeding, immediate withdrawal and antagoniza-
tion of the anti-thrombotic drug is mandatory and close coop-
eration with the neurosurgeon is needed.
Urogenital bleeding (0.5–1.5%) is usually temporary and
not associated with the need for a blood transfusion or
surgical intervention.
Occasionally one can see bleeding in respiratory tract or
significant drops of hemoglobin without a clinically proven
bleeding site.
Retroperitoneal bleeding (which can be difficult to diagnose)
is pure non-access bleeding when other than femoral approach
for coronary catheterization and intervention is used.
5.2. Access site bleeding
Puncture site for the primary PCI is the most frequent source
of bleeding. These complications in clinical practice include
large hematomas in the groin, arterio-venous (AV) fistulas,
aneurysms and pseudoaneurysms of artery or retroperitoneal
bleeding. Fortunately, these complications may be substan-
tially reduced when the radial approach is used in an
experienced center. Although the radial artery is superficial
and hemostasis can be achieved easily, access site bleeding
can occur that, if left unchecked, can lead to forearm
hematoma and rarely, to compartment syndrome [46].
In case of femoral approach the use of closure device may
be considered. However, studies have not shown a significant
benefit in terms of a reduction in access site complications,
including bleeding risks. The main advantage of closure
devices is that they are more comfortable for patients.
Jolly et al. in 2009 documented the benefit of the radial vs.
femoral approach in the first large meta-analysis on the
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patients who had been randomized to trans-radial approach
(TRA) vs. trans-femoral approach (TFA). This analysis showed
a remarkable and highly significant 73% reduction of major
bleeding complications in the TRA arm. Interestingly, this
dramatic reduction of major bleeding complications was also
associated with a trend toward fewer deaths, myocardial
infarctions, and strokes (OR 0.71; 95% CI, 0.4–1.01; p¼0.06)
in TRA compared to the TFA group.
The benefit of TRA over TFA (both lower morbidity and
cardiac mortality) was subsequently documented in a meta-
analysis by Mamas et al. [48]. The researchers chose 9 studies
from 2003 to 2011 and included a total of 2977 STEMI patients.
Within the studies, 1460 patients underwent transradial PCI
and 1517 patients had transfemoral PCI. Patients with the
TRA had a 45% relative reduction in major bleeding; addi-
tionally, a 70% reduction in access site complications and 48%
relative reduction in mortality were found.
The next meta-analysis, comparing the radial and femoral
approach in primary PCI for STEMI was published by Joyal
et al. [49]. The study included 10 trials involving 3347
patients. The inclusion criteria were a randomized study
design, a patient with documented STEMI undergoing pri-
mary PCI, a control group undergoing femoral access, and the
type of clinical outcome (death, major bleeding, vascular
complications, or hematoma), and procedure time. The radial
approach was associated with improved survival (OR 0.53;
95% CI, 0.33–0.84, p¼0.93) and reduced vascular complica-
tions/hematoma (OR, 0.35, 95% CI, 0.24–0.53, p¼0.66). A non-
significant trend was found toward reduced major bleeding
using the radial approach (OR 0.63; 95% CI, 0.35–1.12, p¼0.79)
The RIVAL trial randomized patients with ACS into inter-
vention by femoral approach vs. the radial approach. In the
STEMI subgroup (1958 patients), the authors found a statis-
tically significant reduction in primary endpoint (death, MI,
stroke and non-CABG bleeding) and non-significant differ-
ence in non-CABG major bleeding (according to OASIS bleed-
ing classification) [50].
The RIFLE-STEACS trial (Radial Versus Femoral Rando-
mized Investigation in ST-Elevation Acute Coronary Syn-
drome) was a multicenter, randomized, parallel-group study
with 1001 acute STEMI patients undergoing primary/rescue
percutaneous coronary intervention. Patients were rando-
mized into the radial (n¼500) or femoral (n¼501) approach
between 2009 and 2011 [51]. Romagnoli et al. reported a
significant reduction in primary endpoint, i.e. 30 day rate of
net adverse clinical events (NACE¼composite of cardiac
death, stroke, myocardial infarction, target lesion revascular-
ization, and bleeding at 30 days): 13.6% in the radial access
group vs. 21.0% in the femoral (p¼0.003). Radial access was
associated with significantly lower cardiac mortality (5.2% vs.
9.2%, p¼0.02) and bleeding (7.8% vs. 12.2%, p¼0.026). Non-
access site bleeding did not differ between groups, but
significant reduction (62%) of access site bleeding was docu-
mented in the radial access group.
Based on the results of the RIVAL-STEMI substudy and the
RIFLE-STEACS study, the ESC 2012 guidelines for STEMI
recommend the preference of radial access over femoral
access for primary PCI (level of recommendation IIaB), if the
procedure is performed by experienced radial operator.6. Prevention of bleeding
The predictors of bleeding are known (see above), but a
specific risk score for STEMI patients regarding a rapid
estimation of bleeding risk has not yet been developed.
In 2009 the CRUSADE bleeding score, for prediction of in
hospital bleeding, was created for NSTEMI patients [52]. The
preference of radial access and/or smaller access sheath size
for coronary catheterization in experienced centers has been
already mentioned. Care of the puncture site after the
intervention is also of importance. For hemostasis, many
radial compression devices exist, for example: Hemostop
(Zoom Co. Medic), Radistop (Radi Medical Systems), RadStat
(Merit Medical Systems), TR Band (Terumo) [53].
Based on an evaluation of both thrombotic and bleeding risk,
tailored treatment strategies should be used for every patient.
One should take into account the age and weight of the patient,
renal function, etc. Moreover, the proper dose and dose adjust-
ment of anti-thrombotic drugs is needed and one should avoid
combinations of anti-thrombotic drugs without proven efficacy
and safety. In the current era, this is of the most importance,
since both novel antiplatelet drugs (ticagrelor, prasugrel) and
anti-coagulants (factors Xa inhibitors-rivaroxaban, apixaban
and thrombin inhibitors-dabigatran) are administered in the
treatment of ACS patients and patients with atrial fibrillation
respectively, but their combinations have not been tested in
clinical trials yet.
One of the most frequent non-access site bleeding complica-
tions is bleeding from a gastroduodenal ulcer and/or erosions. In
recent years, possible interactions between proton pump inhibi-
tors (PPI, namely omeprazole) and clopidogrel (possibly resulting
in reduced clopidogrel effect) systems have been discussed.
Although laboratory proven, the interaction between clopidogrel
and omeprazole has not been shown to increase cardiovascular
risks with drug coadministration in patients with ACS, whereas a
significant reduction in gastrointestinal bleeding with PPIs use
was observed [54]. The retrospective CALIBER study (UK 2012)
included 24,471 patients with ACS. Patients were prescribed
clopidogrel and aspirin and 12439 (50%) also PPI. The interaction
between the PPI and clopidogrel was not clinically important [55].
Therefore, concurrent clopidogrel and PPI use (with the possible
preference of pantoprazole) appears safe, but co-prescription is
recommended only for patients at risk for gastrointestinal
complications.
Novel P2Y12 blockers (ticagrelor, prasugrel) do not have any
interactions with PPI, are more efficient than clopidogrel, but
this also suggests a need for more widespread PPI use during
DAPT (or triple antithrombotic therapy). Based on ESC 2012
STEMI guidelines, PPI should be considered for patients with a
history of GI bleeding and are appropriate for patients with
multiple risk factors, such as advanced age, anti-coagulation,
steroids, NSAIDs. H2 blockers are insufficient in prevention
(5 times weaker than PPI for upper GI bleeding prevention).
There are several specific patient subgroups for higher
risks of bleeding e.g. patients with renal insufficiency or
patients undergoing surgery. In addition, difficult clinical
scenarios can occur when STEMI patients also require long-
term anti-coagulation, i.e. patient with mechanical valve or
atrial fibrillation with CHA2DS2VASC score Z1. In these
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thrombi or stent thrombosis) and bleeding risks, which may
be estimated using the HAS-BLED score, it is preferable to
implant a bare metal stent instead of drug eluting stent
unless the latter is absolutely indicated. The second point is
the strategy of long-term post-PCI anti-thrombotic treatment.
When anti-coagulant treatment is indicated, it cannot be
replaced by anti-platelet agents; therefore the dilemma is the
type and duration of anti-platelet therapy. Higher HAS-BLED
score (Z 3 points) does not necessarily indicate antithrom-
botic treatment cessation, but clinicians should be very
careful and intensify monitoring for bleeding occurrences.
Current ESC guidelines recommends triple therapy (oral
anticoagulantþaspirinþclopidogrel) and the duration of DAPT is
based on the type of stent and type of the event (i.e. elective PCI
vs. PCI in ACS). It is well known, that this triple therapy is
associated with significantly higher bleeding risks. The recently
published WOEST trial compared OACþDAPT (aspirinþclopido-
grel) vs. oral anticoagulantþclopidogrel (without aspirin) [56].
Approximately one third of the patient population had ACS. The
authors observed significantly higher incidences of bleeding in
triple therapy group and interestingly also higher mortality and
combined endpoint at 12 months in the triple therapy group
(Fig. 5). Further and larger studies are clearly needed with this
specific patient population. At present, triple therapy with oral
anticoagulantþaspirinþprasugrel or ticagrelor is not recom-
mended since it might increase the risk of bleeding.
The most frequent reason for P2Y12 inhibitors and/or
aspirin cessation is surgery, bleeding and non-compliance
of the patient with treatment. Dual antiplatelet therapy is
recommended for 12 months after STEMI events. During this
period the patient may require planned or urgent non-cardiac
surgical procedures. Antiplatelet therapy maintenance or
withdrawal in these scenarios is not based on evidence, but
on expert opinion taking into account the bleeding risk of the
procedure and time after STEMI. Duration of stent endoteli-
sation is in detail discussed in Section 7. At this point we will
summarize briefly our local strategy, which is based on the
data from literature [57,58].(1)Fig
str
tarPatients on aspirin monotherapy (usually longer than 12
months after a STEMI event).
Prior to surgery, aspirin can be continued without inter-
ruption, with the exception of intracranial and selected. 5 – WOEST trial. 1 year results. Composite end point
oke, myocardial infarction, death, stent thrombosis,
get vessel revascularization [56].ophthalmic surgery, where aspirin should be discontinued
7 days prior to surgery.(2) Patients on dual antiplatelet therapy (DAPT).
a) High risk situations (bare-metal stent (BMS) placement
within the previous 12 weeks and drug-eluting stent
(DES) implanted within previous 6–12 months, anytime
in patients with a history of stent thrombosis, stent in
left main coronary artery and/or last patent coronary
artery or coronary artery bypass, etc.)
Postpone the surgery if possible. If the surgery is
mandatory, DAPT should be continued. Only 6–12
months after BMS implantation (when the benefits of
early operations prevail) or in cases of neurosurgical/
selected ophthalmological procedures maintain aspirin
and withdraw the P2Y12 blocker 7 days before surgery.
b) Low risk situations (not fulfilling criteria 2a)Before the majority of surgical procedures, aspirin shouldbe continued and the P2Y12 blocker withdrawn 7 days before
surgery. In dental procedures, DAPT is maintained. In patients
undergoing intracranial and selected ophthalmic surgery,
withdrawal of DAPT should be considered (at least the P2Y12
blocker).
Management of all above mentioned situations require a
close multidisciplinary approach (cardiologist, anesthesiolo-
gist and surgeon) in the pre-, peri- and postoperative period.7. Treatment of bleeding and discontinuation
of antiplatelet therapy
The treatment of clinically significant bleeding is primarily
based on attempts to control the source of bleeding. In access
site bleeding after pPCI it is necessary to extract the femoral
sheath with subsequent careful compression. For severe
gastrointestinal bleeding it is an early endoscopic exam and
treatment, i.e. PPI in continual i.v. infusion in doses of 8 mg/h
for the first 3 days. With respect to a temporary withdrawal of
antiplatelet drugs (aspirin or P2Y12 antagonist or both), the
optimal strategy in patients on DAPT and peptic ulcer bleed-
ing remains to be determined and should be tailored to every
patient.
If there is a suspicion of intracranial bleeding, a CT scan is
urgently indicated and after confirmation of a brain hemor-
rhage, consultation with neurosurgery is required. If there is
urethral bleeding, then the insertion of urethral 3 way
catheter is needed.
In life-threatening bleeding, the immediate discontinua-
tion and eventually antagonism of anti-platelet therapy is
indicated (antidotes—see Table 3) [58].
Administration of a transfusion and/or platelets must be
reserved for only serious bleeding with circulatory instability,
because inappropriate transfusion of red cells worsens the
prognosis. Premature discontinuation of anti-platelet therapy
may be at the cost of increased incidences of cardiovascular
mortality and morbidity [59].
In an Italian study [60] with 1358 patients (STEMI 30%)
after PCIþdrug eluting stent (sirolimus-eluting stent 707
patients and paclitaxel-eluting stent 651 patients), early
discontinuation of clopidogrel and/or aspirin (in the first
Table 3 – Managing bleeding in patients on anticoagulants and antiplatelets [57].
Medication Treatment
Aspirin, P2Y12 inhibitor Transfuse platelets to raise count by 50,000/ul
Glycoprotein IIb/IIIa
inhibitor
Stop infusion of abciximab if given, transfuse platelets to raise count by 50,000/ul
Warfarin  If INR is 5–9 and no bleeding, discontinue warfarin, consider vitamin K
and recheck INR within 24 h
 If INR is 49 and no bleeding, discontinue warfarin, give 5 mg oral vitamin K
and recheck INR within 24 h
 If major bleeding is present, administer 3–5 units FFP and 10 mg vitamin K
(subcutaneus) or slow intravenous infusion
 If is INR o5 and no bleeding, stop warfarin and recheck INR within 24 h
Enoxaparin Protamine may be effective. Dose 1 mg protamin per 1 mg enoxaparin
Heparin 1 mg protamin i.v. per every 100 units heparin given over previous 4 h (to maximum
50 mg)
INR—international normalized ratio, FFP—fresh frozen plasma.
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(7.6% vs. 3.4% p¼0.038), MACE (28.6% vs. 13.7% po0.001) and
cardiovascular death (5% vs. 1.2%, po 0.007).
Premature discontinuation of dual antiplatelet treatment is
strongly associated with stent thrombosis, which may manifest
as STEMI, malignant arrhythmias or even sudden death [61].
Stent thrombosis is a platelet mediated process that occurs
through progressive platelet activation and aggregation ulti-
mately leading to thrombus formation. PCI causes endothelial
and tunica media damage that heals via neointimal formation.
This process usually lasts up to 6–12 weeks with bare metal
stents (BMS) and up to 6–12 months with drug eluting stents [62].
It seems that time to endothelization will be decreased with the
newest generations of DES, either second generation, or DES
with bioresorbable polymers and fully bioresorbable stents [63].
Hopefully, the recommended duration of DAPT after STEMI
events can be shortened. In December 2013 we expect results
from the DAPT STEMI study [64]—a randomized, open label trial
of 6 months vs. 12 months with dual anti-aggregation therapy
(aspirinþprasugrel or ticagrelor) after pPCIþdrug eluting stent.
Discontinuation of aspirin increases risk of CV morbidity and
mortality in patients with cardiovascular comorbidities. A retro-
spective trial from Sweden with 118 patients after aspirin
discontinuation documented that 44 of 118 patients (37%) either
died or developed acute cardiovascular events. It means that
patients with cardiovascular comorbidities who stop low-dose
aspirin therapy had an almost 7-fold increased risk for death or
acute cardiovascular events (hazard ratio, 6.9; 95% confidence
interval, 1.4–34.8) compared to patients continuing this therapy
during the first 6 months of the follow-up period. On the
contrary, such an association was not observed among patients
without cardiovascular comorbidities [65].8. Future
Although prasugrel and ticagrelor act more quickly than
clopidogrel, there remains a need for an affective intravenous
formulation of a P2Y12 blocker in patients before surgical
intervention, patients with impossible or impaired gutabsorption (e.g. after cardiopulmonary resuscitation, cardio-
genic shock, mechanical ventilation with deep sedation, etc.).
It is also important to have agents that are rapidly reversible
in patients awaiting surgical intervention.
New agents (e.g. vorapaxar) are in development. There is
also a place for testing new combinations of drugs. The
BRAVE-4 study (prasugrelþbivalirudin vs. UFHþclopidogrel)
is under way. The question is whether aspirin will remain an
indispensable part of anti-platelet therapy in the era of
newer, more potent P2Y12 inhibitors and if novel anti-
coagulants can be combined with other anti-platelet agents.
Recent developments in catheters and closure devices have
opened other fields regarding improvements in primary PCI
results with reduced risks of bleeding.
Last but not least, genetic testing will be probably used
more widely in clinical practice as a method of individualiz-
ing patient care.9. Conclusion
Patients with acute myocardial infarction with ST segment
elevation are indicated for combined anticoagulant and dual
antiplatelet treatment as soon as possible after establishing
the diagnosis with subsequent early primary PCI with stent
implantation. Dual antiplatelet therapy is then administered
usually for one year. This strategy, which reduces immediate
and long-term ischemic risks carries a higher short-term and
long-term risk of bleeding, which is a very important pre-
dictor of morbidity and mortality. The preference of radial
access in centers experienced with the procedure signifi-
cantly reduced bleeding complications and improved clinical
outcomes in STEMI patients. After individual stratification of
thrombotic and bleeding risks one should apply measures to
reduce the risk of these complications using effective and
safe combinations of antiplatelet and anticoagulant agents
while minimizing the risks of bleeding. Similarly, when
bleeding occurs, a tailored treatment approach should be
applied for each individual patient.
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